Jane S. Ricciuti, RPh, MS


March 19, 2003

In This Article

Antineoplastic Agents

(leuprolide acetate) Injection

Manufacturer: Atrix Laboratories, Inc.

Drug Approval Classification: Original New Drug Application (Approval Date: 02/13/03)

New Indication: This new drug application provides for the use of Eligard (leuprolide acetate for injectable suspension) for the palliative treatment of advanced prostate cancer.

Dosing: Eligard 30 mg subcutaneously once every four months.

Eligard (leuprolide acetate) Injection Labeling

Eligard (leuprolide acetate) Injection


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.